Novo Nordisk says experimental drug amycretin present 13% weight reduction in trial
Enterprise & FinanceWell being
07 March 2024, 2:04 pm 1 minute
Reuters was first to report on the early trial information for Novo Nordisk’s extremely anticipated experimental drug amycretin which confirmed that individuals had a weight lack of 13.1% after 12 weeks, prompting the corporate’s shares to rise to document highs and putting it above Tesla by market valuation.
Market Impression
Shares surged greater than 8% to document highs, capturing Novo Nordisk up in world rankings to the twelfth most respected firm from 14 beforehand.
Article Tags
Matters of Curiosity: Enterprise & FinanceWell being
Sort: Reuters Finest
Sectors: Enterprise & FinancePrescribed drugs & Healthcare
Areas: Americas
International locations: United States
Win Varieties: Exclusivity
Story Varieties: Unique / Scoop
Media Varieties: Textual content
Buyer Impression: Vital Nationwide Story
